Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 18;12(2):e003333.
doi: 10.1136/openhrt-2025-003333.

Improved diagnosis of COVID-19 vaccine-associated myocarditis with cardiac scarring identified by cardiac magnetic resonance imaging

Affiliations

Improved diagnosis of COVID-19 vaccine-associated myocarditis with cardiac scarring identified by cardiac magnetic resonance imaging

Josephine Warren et al. Open Heart. .

Abstract

Background: Myocarditis is a rare but potentially serious complication of COVID-19 vaccination. Cardiac magnetic resonance (CMR) with late gadolinium enhancement (LGE) imaging can identify cardiac scar, which may improve diagnostic accuracy and prognostication. We sought to define the incidence of long-term LGE post COVID-19 vaccine-associated myocarditis (C-VAM) and to establish the additive role of CMR in the diagnostic workup of this condition.

Methods: Patients with Brighton Collaboration Criteria Level 1 (definite) or Level 2 (probable) C-VAM were prospectively recruited from the Surveillance of Adverse Events Following Vaccination In the Community database to undergo CMR at least 6 months after diagnosis. As there were limited patients with access to baseline CMR, prior CMR results were not included in the initial case definition. The presence of LGE at follow-up CMR was then integrated into the diagnostic algorithm, and the reclassification rate (definite vs probable) was calculated.

Results: 67 patients with C-VAM (mean age 30±13 years, 72% male) underwent CMR evaluation. The median time from vaccination to CMR was 548 (range 398-603) days. 20 patients (30%) had LGE. At diagnosis, nine patients (13%) were classified as definite and 58 (87%) as probable myocarditis. With the integration of CMR-LGE data, 16 patients (28%) were reclassified from probable to definite myocarditis.

Conclusion: LGE on CMR occurred in one-third of patients with C-VAM. Without CMR at the time of diagnosis, almost one-third of patients are misclassified as probable rather than definite myocarditis, indicating a diagnostic strategy using echocardiography alone is insufficient.

Keywords: COVID-19; MYOCARDIAL FIBROSIS; Myocarditis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1. Example of a patient with late gadolinium enhancement on CMR. Follow-up cardiac MRI demonstrating late gadolinium enhancement (red arrows) in the mid-inferior and inferolateral segments. CMR, cardiac MRI.
Figure 2
Figure 2. Distribution of left ventricular late gadolinium enhancement. Distribution of late gadolinium enhancement according to the 17-segment model of the left ventricle. Red represents the most frequent location and white the least. The most common location for late gadolinium enhancement on follow-up cardiac MRI was the basal inferolateral segment.
Figure 3
Figure 3. Brighton Criteria reclassification based on late gadolinium enhancement on follow-up CMR. Almost a third of patients (16 of 56, 28%) who were originally diagnosed with probable myocarditis were found to have late gadolinium enhancement on cardiac MRI, resulting in reclassification to definite myocarditis. CMR, cardiac MRI.

References

    1. Watson OJ, Barnsley G, Toor J, et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22:1293–302. doi: 10.1016/S1473-3099(22)00320-6. - DOI - PMC - PubMed
    1. World Health Organization WHO coronavirus (covid-19) dashboard. 2023. https://data.who.int/dashboards/covid19/vaccines Available.
    1. Australian Government Department of Health and Aged Care COVID-19 vaccine rollout. 2023.
    1. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med. 2021;385:2132–9. doi: 10.1056/NEJMoa2110737. - DOI - PMC - PubMed
    1. Lai FTT, Chan EWW, Huang L, et al. Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis. J Am Coll Cardiol. 2022;80:2255–65. doi: 10.1016/j.jacc.2022.09.049. - DOI - PMC - PubMed

MeSH terms

Substances